Abstract Evidence points to an association of prolactin to autoimmune diseases. We examined the correlation between hyperprolactinemia and disease manifestations and activity in a large patient cohort. Age-and sex-adjusted prolactin concentration was assessed in 256 serum samples from lupus patients utilizing the LIASON prolactin automated immunoassay method (DiaSorin S.p.A, Saluggia, Italy Rev Allerg Immunol (2012) 42:189-198 DOI 10.1007 (42% vs. 26%, p=0.02) and marginally more proteinuria (65.5% vs. 46%, p=0.06). Elevated levels of prolactin were not significantly associated with other clinical manifestations, serology, or therapy. Disease activity scores were not associated with hyperprolactinemia. Hyperprolactinemia in lupus patients is associated with all types of serositis and anemia but not with other clinical, serological therapeutic measures or with disease activity. These results suggest that dopamine agonists may be an optional therapy for lupus patients with hyperprolactinemia.
Introduction
Prolactin (PRL) is a polypeptide hormone secreted by the anterior hypophysis. It is an integral member of the immunoneuroendocrine network and has a role in the pathogenesis of autoimmune diseases mainly systemic lupus erythematosus (SLE).
Prolactin Structure Secretion and Function
Pituitary monomeric free PRL (little PRL, 23 kDa) is the main PRL isoform. Other isoforms include big PRL (56 kDa) and big big (macro) PRL (150-160 kDa). Macro PRL is mostly constituted by IgG monomeric PRL complex [1] . The different isoforms that are secreted from immune cells have variable biologic activity [2] . The PRL receptor belongs to type 1 cytokine/hematopoietic receptor super family [3] .
PRL secretion is inhibited by the hypothalamus via dopamine. Thyroid releasing hormone, hypothyroidism, and adrenal insufficiency stimulate PRL secretion by inhibiting dopamine secretion. The main cytokines stimulating PRL secretion are interleukin (IL)-1, IL-2, and IL-6 while interferon-γ and endothelin 3 are inhibitory [4] .
Besides breast feeding, chest wall stimulation and chest wall injury stimulate PRL secretion. Medications that increase PRL secretion by inhibition of dopamine secretion include neuroleptic drugs phenothiazines and haloperidol, antihypertensive medications calcium channel blockers and methyldopa, tricyclic antidepressants, H 2 antagonists, and opiates. Decreased elimination of PRL due to renal or hepatic failure increases PRL level. Estrogen has an important role in PRL secretion in pregnancy and other conditions. Prolactinoma is another cause of very high levels of prolactin [5] .
PRL is synthesized in several organs including neurons, mammary epithelium, prostate, endothelium, and skin [4] . PRL is synthesized also in immune organs including the thymus, spleen, lymph nodes, and bone marrow as well as in mononuclear cells (mainly lymphocytes). The human PRL gene is located on chromosome 6. Its expression is at multiple extrapituitary sites, where it is under tissue-specific control [6] .
Estrogen has a role in the regulation of PRL gene expression in humans [7] . PRL secreted from the hypophysis acts as a hormone, while the PRL produced by extrahypophyseal organs functions as a cytokine as it is synthesized in multiple sites, has similar receptor structures and signal transduction pathways [8, 9] . PRL receptors are distributed throughout the immune system and are included in the cytokine receptor family that includes receptors for IL-2β chain, IL-3, IL-4, IL-6, IL-7, growth hormone, and erythropoietin [10] .
PRL's main physiological role is to regulate the growth and differentiation of the mammary gland and ovary, to initiate and sustain lactation and regulate maternal behavior. Other functions include role in osmoregulation, calcium metabolism, reduction of the threshold for glucosestimulated insulin secretion, anti-angiogenesis, vasoconstriction, and anti-vasopermeability actions. Nevertheless, in recent years, PRL's role in immune regulation was defined [11] .
The Role of Prolactin in Immune Modulation
Experimental studies in lupus murine models have shown that hyperprolactinemia (HPRL) can interfere with B cell tolerance induction by impairing the B cell receptormediated clonal deletion, deregulating receptor editing and decreasing the threshold for activation of anergic B cells [12, 13] .
Lupus murine model studies also demonstrated that PRL induces a decrease in apoptosis of transitional B cells thereby contributing into the breakdown of B cell tolerance to self and to the development of autoimmunity [14] . PRL induces the production of IL-1 and interferon-γ and promotes the expression of IL-2 receptor [15] . In addition, HPRL affects dendritic cell (DC) maturation, skewing DC function from antigen presentation to pro-inflammatory phenotype with increased interferon α production [16] . Moreover, PRL also enhances immunoglobulin production [17] . PRL regulates the maturation of CD4− CD8− thymocytes to CD4+ CD8+ T cells via IL-2 receptor expression and leads to the enhancement of pro-B cell generation [12] .
Hyperprolactinemia and Autoimmune Diseases
The mechanisms above may have a role in the increased prevalence of autoimmune diseases in patients with HPRL. Moreover HPRL is observed in various autoimmune diseases [18] . HPRL has been demonstrated in multiorgan diseases as SLE, rheumatoid arthritis (RA), systemic sclerosis (SSc), Sjögren's syndrome (SS), and reactive arthritis [18] .
The organ-specific diseases correlated with HPRL include type 1 diabetes mellitus, Graves' disease, Hashimoto's thyroiditis, Addison's disease, lymphocytic hypophysitis, celiac disease, multiple sclerosis, uveitis, and rejection of heart transplantation [18, 19] .
Systemic Lupus Erythematosus
SLE is more common in women of reproductive age, and this 9:1 ratio compared to men, with sex hormones estrogen and PRL implicated as explanatory mechanisms [12] .
Mild to moderate HPRL is reported in 15-45% of SLE patients [20] [21] [22] [23] [24] [25] [26] , compared to a rate of 3% in the general population [27] . Studies on the correlation of PRL levels and disease activity in SLE were inconsistent [18] .
Few studies of dopaminergic agonist therapy for reducing PRL levels were effective in experimental models of lupus and small clinical trials in SLE [28] [29] [30] [31] [32] [33] .
Inhibition of PRL secretion by bromocriptine decreased serum anti-double-stranded DNA (ds-DNA) antibody titers and improved the survival of lupus-prone mice [29] , and mice with estrogen-induced HPRL [30] .
Bromocriptine therapy showed a beneficial effect in SLE patients suffering from mild to moderate active disease and led to a significant improvement in disease activity scores [25, 31, 32] . Further, discontinuation of bromocriptine therapy was followed by a flare of disease activity [32] . In another study, the role of additional therapy with bromocriptine 2.5 mg/day added to 10 mg prednisone was found to be beneficial for pregnant SLE patients. In this study, the added therapy given during weeks 25-35 of gestation prevented lupus flare, premature rupture of membrane, and preterm birth [33] .
Alternative therapy with low-dose quinagolide added to the existing therapy of 25 SLE patients for 3 months diminished significantly SLE patient's PRL and IL-6 levels with a significant reduction of SLEDAI score compared to baseline [34] .
Rheumatoid Arthritis
The studies on PRL levels in RA found inconsistent results, varying from lower, equal to higher PRL serum levels [35] . RA usually improves during pregnancy and may exacerbate after delivery, a period when cortisol and estrogen decline and PRL increases [36] . The risk of RA is increased in women who breastfeed after the first pregnancy. The propensity to develop RA was suggested to be related to immune stimulation by PRL [36, 37] . The dynamic response of hypothalamic-pituitary-adrenal axis and PRL pituitary secretion in women under 40 years old with RA showed upregulation of PRL secretion while the level of adrenocorticotropine hormone (ACTH) and cortisol did not increase after corticotropine releasing hormone test [38] . However, in newly diagnosed untreated RA patients the level of PRL, ACTH, and cortisol in response to stimulation test was the same as in the controls [39] . In ten postmenapausal active RA women, a lower ACTH and cortisol level, respectively and higher PRL and PRL/ cortisol ratio at 2:00 a.m. were demonstrated when compared to controls [40] .
The PRL response to induced hypoglycemia in active RA was decreased and normalized after 6 months of therapy with disease-modifying anti-rheumatic drugs (DMARDs) [41] . However, another group could not find a significant difference in PRL response to induced hypoglycemia in glucocorticoid-naive premenopausal patients with RA [42] .
The pro-inflammatory cytokine macrophage inflammatory protein-1α is produced by cells involved in the inflammatory rheumatoid process and may stimulate pituitary production of PRL [43] . PRL is also produced in the rheumatoid joint by fibroblast like synovial cells and by T lymphocytes infiltrating the synovium and increases the synthesis of matrix metalloproteinase-3, IL-6, and IL-8. PRL seems to stimulate collagenase activity and to act as a growth factor for lymphocytes. Bromocriptine suppresses in vitro the expression of messenger RNA for PRL and tumor necrosis factor α in the synovial cells and infiltrating lymphocytes [44] . These findings suggest that PRL may have a role in initiating or sustaining the inflammation in RA, but it is not clear if the stimulation is produced by pituitary PRL or by PRL of lymphocyte origin.
Three small cohorts of RA patients demonstrated normal level of PRL in comparison with controls [39, 45, 46] . Among 60 RA women, HPRL or macroprolactinemia were not more prevalent compared with controls; however, serum PRL and free (monomeric) PRL were significantly elevated in RA compared to controls [47] . Male RA patients showed high serum PRL levels. The serum PRL concentration was found to be increased in relation to the duration and the activity of the disease [48] . Another cohort of 91 RA male patients demonstrated HPRL in 40% of them. Men with RA had high serum PRL levels in comparison to control group. PRL level correlated with longer disease evolution and worse functional stage [49] . Among 53 RA patients, we demonstrated HPRL in three (6%), this is twice the prevalence in a healthy population [50] . In a recent study, serum and synovial PRL levels were significantly higher in 29 RA patients compared with osteoarthritis patients. Serum PRL level correlated with total Larsen score meaning more severe radiographic damage and synovial PRL levels correlated with disease activity measured by DAS 28 score [35] . Bromocriptine treatment for RA was tried in four small open-label trials. Bromocriptine 6.25 mg in addition to cyclosporine in six RA patients did not improve clinical or laboratory measures of disease activity [51] . In 30 active RA patients, bromocriptine therapy improved clinical activity as penicillamine, but failed to improve laboratory parameters of inflammation [52] . Five refractory RA patients were treated with 5 mg bromocriptine once daily. Three of them improved more than 25%, but only in two, the improvement lasted till the end of study therapy at 6 months. No correlation was found between PRL levels and disease activity [53] . Nine seropositive postmenapausal RA patients that discontinued DMARDs because of inefficacy or adverse effects were treated for 3 months by bromocriptine 5-30 mg daily according to tolerance. Clinical improvement was significant in morning stiffness and HAQ disability index. Four patients fulfilled the American College of Rheumatology criteria for RA improvement. There was correlation between clinical improvement and reduction in immune activity including peripheral blood mononuclear cells to antigen and production of IL-2 and nitric oxide [54] .
Nine normoprolactinemic RA patients were treated by quinagolide in addition to prednisone and non-steroidal anti-inflammatory drugs for 6 months. There was no clinical or laboratory improvement with quinagolide [55] . There is a single case report of cabergoline therapy for prolactinoma improving the RA manifestations [56] .
Multiple Sclerosis
In studies in experimental allergic encephalomyelitis (EAE) the animal model of multiple sclerosis (MS) PRL levels were elevated before the onset of neurological manifestations. Bromocriptine therapy was protective when initiated 1 week after the initial immunization and also suppressed late disease [57] . Bromocriptine reduced the severity and duration of EAE in chronic relapsing model [58] .
Studies that evaluated the serum levels of PRL in MS patients have yielded conflicting results. Mild to moderate HPRL was found in 30% of MS patients and was speculated to be related to hypothalamic lesions [59] . Twelve MS patients had elevated PRL levels in comparison with controls without HPRL. The PRL levels post-TRH stimulation were significantly higher in patients with MS when compared with control group [60] . PRL levels were measured in 49 MS patients and healthy controls. Excessive concentration of PRL in blood serum was observed in the menstruating women with MS and male MS patients in comparison to healthy menstruating women and men [61] .
HPRL in Japanese female patients with an opticospinal variant of MS (termed Asian type) was associated with hypothalamic lesions. All MS patients with HPRL showed recurrent opticomyelitis and a higher Expanded Disability Status Scale score. Severe inflammation in the optic nerves may spread and damage the adjacent tuberoinfundibular dopaminergic neurons, which inhibit PRL secretion [62] . Among 68 male MS patients, the rate of HPRL was 16.2%; however, the mean PRL level was not significantly different from the mean PRL level in the control group. There was no difference in PRL level between the relapsing-remitting and the progressive type of MS [63] . PRL levels in serum and cerebrospinal fluid (CSF) were found to be significantly higher in female relapsing-remitting MS patients but not in males. No associations were found with disease activity, disease duration, presence of active lesions, or the presence of oligoclonal bands in CSF. This could be suggestive of a sexually dimorphic response to central nervous system injury as a result of an increased proneness of females to synthesize and release PRL, which is possibly linked to the relatively more favorable prognosis of MS in women [64] . In our recent study, HPRL was documented in 10/150 (6.7%) MS patients significantly more common compared with healthy controls. Among female MS patients, HPRL was related to the secondary progressive type of disease [65] . A case reported of a relapsing-remitting MS patient who experienced the first MS clinical event during the development of a PRL secreting adenoma and the only two MS relapses were during adenoma recurrence. PRL may have facilitated the inflammatory process and triggered MS clinical attacks [66] . Other studies did not find difference in PRL levels between MS patients and healthy controls and PRL level was not correlated with clinical disease activity or disease duration [67] [68] [69] [70] . The role of bromocriptine in therapy for MS was suggested; however, an open-label pilot study did not show therapeutic effects on MS activity [71] . A study of intravenous methylprednisolone therapy 500 mg monthly caused a reduction of T2 lesion volume with a parallel decline in plasma PRL in nine relapsing-remitting MS patients [72] .
Systemic Sclerosis
SSc is at least five times more common in women in childbearing age than in men [73] . That may suggest a pathogenic role of sex hormones in SSc. PRL serum levels were high in a wide range of 3-81% of patients suffering from SSc in different cohorts [6, 50, [74] [75] [76] . A possible explanation of HPRL in SSc may be the sustained release of PRL over 24 h and a change in the diurnal rythm with peaks of secretion between 6 and 11 a.m., instead of 2-6 a.m. [74] . Basal and after stimulation with thyroid releasing hormone PRL levels were found to be higher than in controls in women suffering from SSc in childbearing age and not in postmenapausal SSc patients in comparison with healthy controls. The HPRL may be a factor in the decreased fertility in SSc. Scores on the SSc organ severity scale were not associated with PRL levels, but PRL level was significantly correlated with skin sclerosis, peripheral vascular, and lung involvement [77] . Basal HPRL and dramatic increase in PRL levels after metochlorpropamide test in SSc patients and not in controls suggest increased dopaminergic tone in SSc. In the same study, CT scan revealed microadenoma in 80% of SSc patients most of them asymptomatic [78] . HPRL in SSc and not in controls was demonstrated, with correlation of PRL level in the diffuse SSc patients with disease manifestations as the rate of skin tethering, diastolic dysfunction of the left ventricle, and disease duration. In all patients, HPRL in early disease was associated significantly with more aggressive skin involvement [75] . SSc patients with severe disease manifestations in comparison with more mild SSc patients have significantly more HPRL and lower serum dehydroepiandrosterone sulfate level. These abnormalities were associated with higher soluble IL-2 receptor (sIL-2R) and vascular cell adhesion molecule [79] . Peripheral blood mononuclear cells (PBMC) supernatants of SSc patients contain significantly increased amounts of PRL as compared to healthy donors' PBMC. These results show that lymphocytes in SSc patients are active producers of extrapituitary PRL. PRLstimulated lymphocytes produced an increased amount of sIL-2R (CD25). The same cells besides producing PRL are also sensitive to PRL stimulation [76] . The cause of HPRL in SSc may be increased dopaminergic tone or secretion of PRL from lymphocytes.
Sjögren's Syndrome HPRL has been reported in 3.6-45.5% of SS patients [50] . Among hyperprolactinemic women, one study found that 75% of them had at least one antibody detected in serum and none in the control group. Anti-SSA was present in 27% and anti-SSB in 12% of hyperprolactinemic women [80] .
Young SS patients with active disease had high prevalence of HPRL associated with internal organ disease, but not with disease duration, serum immune globulins, autoantibodies, or focus score in minor salivary gland biopsy [81] . HPRL was found in 45.5% of SS patients and not in control group, without any correlation between HPRL and systemic manifestations or presence of autoantibodies [82] . Another group did not find correlation between PRL levels and systemic disease manifestations nor with hormonal status or autoantibodies [27] .
The presence of PRL and PRL receptor was detected by immunohistochemistry in ductal epithelial cells of minor salivary glands in SS and not in the lymphocytes infiltrating around the ducts. Big PRL of 60 kDa and a 16-kDa PRLlike protein were demonstrated. A positive correlation was found between the presence of PRL-like proteins in acinar epithelial cells of SS patients and clinical extraglandular manifestations. The presence of anti-Ro and anti-La antibodies also positively correlated with a higher percentage of PRL in acinar epithelial cells demonstrating local synthesis of PRL-like proteins in the acinar ducts in salivary glands [83] . A central deficiency in all three neuroendocrine axes: adrenal, gonadal, and thyroid was found in SS with elevated PRL levels, probably affects immune function in SS patients [84] Autoimmune Thyroid Disease Hashimoto's thyroiditis patients exhibit significantly higher PRL and lower cortisol levels than healthy controls [85] . Nineteen percent of patients with Hashimoto's thyroiditis had HPRL; however, the prevalence of HPRL in the primary hypothyroid group was much higher (42.4%) than in euthyroid patients that were not different from the control group [86] . HPRL induced by anti-psychotic medications in schizophrenic patients, who did not have clinical thyroid disease, is related with significantly increased thyroid antibodies [87] .
In our previous study, HPRL was detected in 24% of polymyositis patients, 21% of lupus patients, 6.7% of multiple sclerosis patients, 6% of rheumatoid arthritis patients, and 3% of systemic sclerosis patients [18] . In SLE, PRL levels did not correlate with lupus disease activity measured by ECLAM score; however, HPRL was significantly associated with anemia and proteinuria.
In the current study, we expanded our cohort to assess the possible association of HPRL with lupus subsets and clinical activity of the disease.
Methods and Patients
Serum samples from 256 SLE patients were evaluated for elevated PRL levels. Patients serum samples were provided by two European clinics: University of Debrecen, Hungary (n=156) and University of Padova, Italy (n=100). Each clinic provided a database including, in addition to demographic characteristics, SLE clinical manifestations, serology, and disease activity scores. Manifestations were further grouped according to organ system involvement consistent with clinical disease and included cutaneous, joints, hematological, renal, and neuropsychiatric findings. Serology included antinuclear antibodies, antibodies to ds-DNA, ENA (Ro/La/ribonucleoprotein particles (RNP)/Sm), cardiolipin, β-2-glycoprotein I, lupus anticoagulant, and C3/C4 levels.
In the Italian patients, disease activity was determined using the ECLAM score (n=100) while in the Hungarian group, SLEDAI score (n=156) was used. Both scores are widely utilized for assessment of disease activity in SLE [88] . In order to unify the description of disease activity for the entire cohort, we chose disease activity cutoffs such that SLEDAI greater than 4 and ECLAM greater than 2 indicating active disease. We evaluated the association of HPRL with medications utilized (corticosteroids, low-dose corticosteroids less than 10 mg of prednisone, anti-malarial drugs, or other medications).
PRL level was detected by the LIASON PRL method. This is a chemiluminescent fully automated immunoassay. Monoclonal antibodies are utilized for the coating of solid phase (magnetic particles) and for the tracer. The tests were performed on the LIASON analyzer (DiaSorin S.p.A, Saluggia, Italy). PRL levels were gender-and ageadjusted. The normal range of PRL in women ≤45 years old is ≤498 mIU/L and in men and women above 45 years old the normal PRL level is ≤392 mIU/L.
Statistical Analysis Clinical manifestations were compared by HPRL (which acquire a value of 0 or 1) using the chisquare test. Continuous variables were compared by an HPRL using the t test for independent samples or the MannWhitney U as appropriate. To preserve the overall alpha of a given organ group, the grouped manifestations were tested by disease activity and if this was found to differ significantly, subsequent by-manifestation testing was performed. All tests were two-sided and significant at p<0.05.
Results
Our cohort was comprised of 256 lupus patients, median age 36.5 years, 88% females, and the mean disease duration was 10.5±7.7 years. HPRL was observed in 46/256 (18%) of lupus patients.
Compared to normoprolactinemic lupus patients, those with HPRL had significantly more serositis (40% vs. 32.4%, p=0.03) specifically, pleuritis (33% vs. 17%, p=0.02), pericarditis (30% vs. 12%, p=0.002), and peritonitis (15% vs. 0.8%, p=0.003) (Fig. 1) .
Compared to the normoprolactinemic SLE patients, hyperprolactinemic subjects exhibited significantly more anemia (42% vs. 26%, p=0.02) and marginally more proteinuria (65.5% vs. 46%, p=0.06) (Fig. 2) .
HPRL was not significantly associated with other disease manifestations as cutaneous, joint, neuropsychiatric, Fig. 1 Results of serositis by prolactin levels comparing normoprolactinemic lupus patients with patients with HPRL Fig. 2 Results of proteinuria and anemia by prolactin levels between normoprolactinemic SLE patients and hyperprolactinemic subjects other hematological or renal manifestations, serology, or any pharmacologic interventions. Disease activity measured either by ECLAM or by SLEDAI score was not associated with the level of PRL.
Discussion
HPRL is associated with lupus disease activity in some human studies [20, 26, [89] [90] [91] [92] . While studies in murine models demonstrate a clear correlation between HPRL and lupus activity [30, 93, 94] , the human data are not consistent. An association between HPRL and more active disease coupled with diminished response to prednisone therapy has been reported [95] , but others, including us, found no correlation between HPRL and lupus activity [18, 22, [96] [97] [98] . The association between HPRL and specific manifestations of SLE was seldom reported.
In the current study, we found an association between high levels of PRL and several manifestations of lupus disease, namely serositis (pleuritis, pericarditis, and peritonitis) and anemia as well as a marginal correlation with proteinuria. This stands in agreement with several other studies. For instance, the level of little PRL (23 kDa) correlated with neurological, renal, and hematological involvement, as well as the presence of serositis, anti-ds-DNA antibodies and low levels of complement. In contrast, macroprolactinemia, anti-PRL antibodies or low levels of little PRL were negatively related to lupus activity [25, 99, 100] .
Others have shown that HPRL is linked to lupus nephritis, central nervous system, cutaneous, and articular manifestations [101, 102] as well as with several autoantibodies, such as anti-ds-DNA, anti-SSA, anti-SSB, anti-Sm, and anti-RNP [103] . Among 30 SLE patients, HPRL was demonstrated in ten patients and PRL levels correlated to disease activity, malar rash, nephritis, and anti-ds-DNA antibody levels [26] . HPRL and decreased serum dehydroepiandrosterone in SLE patients was associated with anti-ds-DNA antibody elevation and a decrease in almost all lymphocyte subsets [104] . Intriguingly, it has been suggested that HPRL in SLE patients increases the disease activity by inducing autoantibodies to phospholipids which are associated by adverse pregnancy outcomes, thus bromocriptine may prevent this effect [28] . HPRL was more prevalent in patients with primary and seconday antiphospholipid syndrome than in healthy population and HPRL correlated with adverse pregnancy outcomes [105] .
The variability of the association between disease activity and organ manifestations and HPRL reported in the literature may be explained by selection bias-specifically, differences in study populations, therapies, abnormal circadian PRL rhythm, and presence of different PRL isoforms and anti-PRL antibodies [101] .
Although in our cohort of 256 patients we found no correlation between HPRL and disease activity scores measured in SLEDAI or ECLAM scores, we found a significantly more serositis (pleuritis, pericarditis, and peritonitis) and anemia and marginally more proteinuria in the hyperprolactinemic SLE patients than in patients with normal PRL levels. However, PRL levels were not measured before and after therapy, and different PRL isoforms were also not examined.
In conclusion, the present study suggests a role for HPRL in SLE and manifestations including serositis and anemia. These findings indicate the need for randomized double-blind placebo controlled trials to study the effect of dopamine agonists as disease-modifying drugs in normoprolactinemic and hypeprolactinemic autoimmune diseases including SLE [106] .
